Watson C, Tallentire CW, Ramage JK, Srirajaskanthan R, Leeuwenkamp OR, Fountain D. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. World J Gastroenterol 2020; 26(25): 3686-3711 [PMID: 32742136 DOI: 10.3748/wjg.v26.i25.3686]
Corresponding Author of This Article
Donna Fountain, PhD, Research Scientist, PHMR Health Economics, Pricing and Reimbursement, PHMR Head Office, London NW1 8XY, United Kingdom. donnafountain@phmr.com
Research Domain of This Article
Oncology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 7, 2020; 26(25): 3686-3711 Published online Jul 7, 2020. doi: 10.3748/wjg.v26.i25.3686
Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review
Catherine Watson, Craig William Tallentire, John K Ramage, Rajaventhan Srirajaskanthan, Oscar R Leeuwenkamp, Donna Fountain
Catherine Watson, Craig William Tallentire, Donna Fountain, PHMR Health Economics, Pricing and Reimbursement, London NW1 8XY, United Kingdom
John K Ramage, Rajaventhan Srirajaskanthan, Kings Health Partners NET centre, Kings College Hospital London, London SE5 9RS, United Kingdom
Oscar R Leeuwenkamp, Advanced Accelerator Applications, Geneva 1204, Switzerland
Author contributions: Watson C and Tallentire CW performed the research and analysed the data; they contributed to the manuscript equally; Ramage JK has reviewed the manuscript and offered invaluable contribution based on his disease expertise; Srirajaskanthan R also provided disease expertise; Leeuwenkamp OR and Fountain D designed and supervised the research. All authors contributed to writing the manuscript; all authors read and approved the final manuscript.
Conflict-of-interest statement: All the authors declare that they have no competing interests.
PRISMA 2009 Checklist statement: This study followed PRISMA guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Donna Fountain, PhD, Research Scientist, PHMR Health Economics, Pricing and Reimbursement, PHMR Head Office, London NW1 8XY, United Kingdom. donnafountain@phmr.com
Received: March 9, 2020 Peer-review started: March 9, 2020 First decision: March 31, 2020 Revised: June 4, 2020 Accepted: June 17, 2020 Article in press: June 17, 2020 Published online: July 7, 2020 Processing time: 120 Days and 0.3 Hours
Core Tip
Core tip: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are slow-growing cancers that arise from diffuse endocrine cells in the gastrointestinal tract and pancreas. An increased emphasis has been placed on health-related quality of life assessment in clinical studies, using reliable and validated patient-reported outcome instruments. Long-term therapeutic options provide symptomatic relief for patients with GEP-NETs, and can slow down or stabilise disease progression, but are not curative. Thus, understanding the impact of the long-term treatment options is particularly important. The aim of this study was to perform a systematic review to assess health-related quality of life focusing on patients with inoperable metastatic GEP-NETs undergoing different treatments in order to uncover areas for future research.
